## CLAIMS

1. Use of Conjugate **1** or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a subject, wherein the Conjugate **1** or a pharmaceutically acceptable salt thereof is to be administered to the subject at a dose of 150 mg/$m^2$, 175 mg/$m^2$, or 200 mg/$m^2$ body surface area.

2. Use of Conjugate **1** or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a subject, wherein the subject has received at least one previous anticancer therapy.

3. Use of Conjugate **1** or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a subject, wherein the subject shows partial response or stable disease after the treatment.

4. The use of any one of claims 1, 2 or 3, wherein the dose of Conjugate **1** or a pharmaceutically acceptable salt thereof is 175 mg/$m^2$.

5. The use of claim 4, wherein Conjugate **1** or a pharmaceutically acceptable salt thereof is to be administered once a week for 3 weeks on Day 1, Day 8, and Day 15 followed with one week of no treatment.

6. The use of any one of claims 1, 2 or 3, wherein the cancer is selected from the group consisting of a cancer of anus, breast, cholangiocarcinoma, colon, Ewing sarcoma, liver, lung, neuroendocrine, ovary, pancreas, salivary gland, and sarcoma.

7. The use of any one of claims 1, 2 or 3, wherein the cancer is pancreatic adenocarcinoma, endometrial adenocarcinoma, liposarcoma, or squamous cell carcinoma of the anus, cervix, or head and neck.

8. The use of any one of claims 1, 2 or 3, wherein the ratio of the tumor Conjugate **1** level to the plasma Conjugate **1** level is more than 5.

9. The use of any one of claims 1, 2 or 3, wherein the tumor Conjugate **1** level is more than 300 nM.

10. The use of any one of claims 1, 2 or 3, wherein the ratio of the tumor SN-38 level to the plasma SN-38 level is more than 3.

11. The use of any one of claims 1, 2 or 3, wherein the tumor SN-38 level is more than 80 nM.

12. The use of claim 1, wherein the subject further receives at least one PARP inhibitor treatment.

13. The use of claim 12, wherein the PARP inhibitor is to be administered on Days 2, 3, 4, 5 and 6 of a 7-day cycle.

14. The use of claim 12, wherein the PARP inhibitor is talazoparib.

15. The use of claim 12, wherein the cancer is small cell lung cancer.

16. The use of claim 12, wherein the subject is HPV positive.

17. The use of claim 1, wherein the subject further receives 5-FU, leucovorin, or a combination of 5-FU and leucovorin.

18. Conjugate **1** or a pharmaceutically acceptable salt thereof, for use in therapy.